Article Text

PDF
Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study
  1. Marc Scherlinger1,2,3,
  2. Claire Carcaud1,2,
  3. Marie-Elise Truchetet1,2,3,
  4. Thomas Barnetche1,
  5. Pierre Duffau1,2,3,
  6. Lionel Couzi1,2,3,
  7. Julien Seneschal1,2,
  8. Patrick Blanco1,2,3,
  9. Estibaliz Lazaro1,2,3,
  10. Christophe Richez1,2,3
  1. 1 Centre Hospitalier Universitaire de Bordeaux, FHU ACRONIM, Bordeaux, France
  2. 2 Université de Bordeaux, Bordeaux, France
  3. 3 CNRS-UMR 5164 Immuno ConcEpT, Bordeaux, France
  1. Correspondence to Dr Estibaliz Lazaro; estibaliz.lazaro{at}chu-bordeaux.fr; Dr Christophe Richez, CNRS-UMR, 5164 Immuno ConcEpT, 146 rue Léo Saignat, 33076 Bordeaux, France; christophe.richez{at}chu-bordeaux.fr

Statistics from Altmetric.com

Many targeted therapies have been developed for systemic lupus erythematosus (SLE) in recent years and almost all have failed to meet their predesigned endpoints.1 Among these therapies, rituximab (RTX) has reported good results in several open-label studies,2 3 but failed to meet its primary endpoints in two randomised controlled trials (RCTs), EXPLORER and LUNAR.4 5

Among the proposed explanations for these failures, the primary outcome criteria’s lack of sensitivity has been suggested.6 The availability of new SLE response criteria led us to reanalyse the EXPLORER study which assessed RTX efficacy in severe non-renal SLE, using four newly available scores: SLE Response Index-4 (SRI-4), a modified SRI-4 (including reduction of glucocorticoids ≤10 mg/day between days 169 and 365), a modified BILAG-based Clinical Lupus Assessment (mBICLA) and a modified Lupus Low Disease Activity Score (mLLDAS), (online supplementary file 1 for details on criteria).7 8

Supplementary data

[annrheumdis-2018-214833-supp1.docx]

The EXPLORER trial was a 52-week, –multicentre, randomised, double-blind placebo-controlled trial of RTX in 257 patients with moderately to severely active non-renal SLE (online supplementary table 1). Patients were randomised at a 2:1 ratio to receive intravenous RTX (1000 …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.